Restricted leptin antagonism as a therapeutic approach to treatment of autoimmune diseases

被引:0
|
作者
Arash Babaei
Sayyed Hamid Zarkesh-Esfahani
Ehsan Bahrami
Richard J. Ross
机构
[1] University of Isfahan,Department of Biology, Faculty of Sciences
[2] University of Malayer,Academic Unit of Diabetes, Endocrinology and Reproduction
[3] University of Sheffield,undefined
来源
Hormones | 2011年 / 10卷
关键词
Adipocyte hormone; Antagonism; Autoimmune disease; Immune response; Leptin;
D O I
暂无
中图分类号
学科分类号
摘要
Leptin, the adipocyte derived hormone, has a pivotal role in regulating energy homeostasis and appetite. Beyond this essential role in bodyweight control, leptin also regulates the immune responses. Leptin has pro-inflammatory effects on T cell populations, shifting the T helper balance towards a TH1 phenotype, through induction of pro-inflammatory cytokines and stimulation of macrophage and natural killer cell function. Acute starvation reduces serum leptin levels, resulting in an impaired cellular immune response. The TH1 pro-inflammatory immune response, a homeostatic response mediated by the low leptin levels, is also impaired during starvation. Leptin-deficient or leptin receptor mutant mice are protected against the development of several inflammatory or various T cell-dependent autoimmune diseases. Therefore, leptin appears to have a central role in the immune response and low leptin levels may protect against autoimmune disease. Here we review the role of leptin in the immune responses, with emphasis on autoimmune diseases. We will also discuss the application of leptin antagonist therapy for prevention and treatment of immunity related disorders.
引用
收藏
页码:16 / 26
页数:10
相关论文
共 50 条
  • [21] SOCS signaling in autoimmune diseases: Molecular mechanisms and therapeutic implications
    Liang, Yan
    Xu, Wang-Dong
    Peng, Hui
    Pan, Hai-Feng
    Ye, Dong-Qing
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2014, 44 (05) : 1265 - 1275
  • [22] Ficolin-1 is a promising therapeutic target for autoimmune diseases
    Katayama, Michihito
    Ota, Kaori
    Nagi-Miura, Noriko
    Ohno, Naohito
    Yabuta, Norikazu
    Nojima, Hiroshi
    Kumanogoh, Atsushi
    Hirano, Toru
    INTERNATIONAL IMMUNOLOGY, 2019, 31 (01) : 23 - 32
  • [23] Therapeutic potential of enhancer of zeste homolog 2 in autoimmune diseases
    Yang, Yue-Xin
    Shen, Hui-Hui
    Cao, Fan
    Xie, Liang-Yu
    Zhu, Guang-Lin
    Sam, Napoleon Bellua
    Wang, De-Guang
    Pan, Hai-Feng
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2019, 23 (12) : 1015 - 1030
  • [24] Therapeutic strategies in autoimmune diseases by interfering with leukocyte endothelium interaction
    Rychly, Joachim
    Nebe, Barbara
    CURRENT PHARMACEUTICAL DESIGN, 2006, 12 (29) : 3799 - 3806
  • [25] Leptin: A new therapeutic target for treatment of diabetes mellitus
    Rehman, Kanwal
    Akash, Muhammad Sajid Hamid
    Alina, Zunaira
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2018, 119 (07) : 5016 - 5027
  • [26] The use of stem cells for the treatment of autoimmune diseases
    Rosa, S. B.
    Voltarelli, J. C.
    Chies, J. A. B.
    Pranke, P.
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2007, 40 (12) : 1579 - 1597
  • [27] IL-19 as a Potential Therapeutic in Autoimmune and Inflammatory Diseases
    Azuma, Yasu-Taka
    Nakajima, Hidemitsu
    Takeuchi, Tadayoshi
    CURRENT PHARMACEUTICAL DESIGN, 2011, 17 (34) : 3776 - 3780
  • [28] NLRP3: A promising therapeutic target for autoimmune diseases
    Shen, Hui-Hui
    Yang, Yue-Xin
    Meng, Xiang
    Luo, Xiao-Yun
    Li, Xiao-Mei
    Shuai, Zong-Wen
    Ye, Dong-Qing
    Pan, Hai-Feng
    AUTOIMMUNITY REVIEWS, 2018, 17 (07) : 694 - 702
  • [29] Bortezomib: a proteasome inhibitor for the treatment of autoimmune diseases
    Khalesi, Naeemeh
    Korani, Shahla
    Korani, Mitra
    Johnston, Thomas P.
    Sahebkar, Amirhossein
    INFLAMMOPHARMACOLOGY, 2021, 29 (05) : 1291 - 1306
  • [30] Bortezomib: a proteasome inhibitor for the treatment of autoimmune diseases
    Naeemeh Khalesi
    Shahla Korani
    Mitra Korani
    Thomas P. Johnston
    Amirhossein Sahebkar
    Inflammopharmacology, 2021, 29 : 1291 - 1306